Immune Checkpoint Inhibitor Associated Cardiovascular Adverse Events in Patients With Cancer
Launched by HANNEKE W. M. VAN LAARHOVEN · Jul 24, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the potential heart-related side effects of a type of cancer treatment called immune checkpoint inhibitors (ICIs). While these treatments have been very effective in fighting various cancers, researchers have noticed that they may increase the risk of serious heart problems, such as blood clots, heart attacks, and strokes. The trial aims to understand how these treatments impact the health of the heart and blood vessels over time, particularly by using a special imaging technique called computed tomography angiography (CCTA) to look at the condition of the coronary arteries.
To participate in this trial, individuals must be at least 50 years old and have a confirmed diagnosis of specific types of cancer, including esophageal, gastric, colorectal, non-small cell lung carcinoma, melanoma, or renal cell carcinoma. Participants should not have received ICI therapy in the last year and must meet certain health criteria, such as not having serious kidney issues or specific infections. If eligible, participants can expect to undergo heart imaging tests to help researchers gather important information about how ICIs may affect cardiovascular health. This study is currently recruiting participants, and it offers an opportunity to contribute to our understanding of how cancer treatments can impact heart health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with confirmed diagnosis of the following tumor types, any stage: esophageal, gastric or junction cancer, colorectal cancer, non-small cell lung carcinoma, melanoma, renal cell carcinoma
- • Prior to start of new therapy (i.e. immune checkpoint inhibitor, chemotherapy or follow-up in case of esophageal cancer)
- • Age ≥ 50 years
- Exclusion Criteria:
- • ICI therapy in previous 12 months
- • Suspected or confirmed viral, fungal, or bacterial infectious disease
- • Use of immunosuppressive therapy prior to ICI start
- • Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m2
- • Known allergy to iodinated contrast agents
- • Atrial fibrillation
About Hanneke W. M. Van Laarhoven
Hanneke W. M. van Laarhoven is a distinguished clinical trial sponsor recognized for her commitment to advancing medical research and improving patient outcomes. With a strong background in clinical oncology and translational medicine, she leads innovative studies that focus on developing new therapeutic strategies and enhancing treatment protocols. Her expertise in trial design, regulatory compliance, and patient-centric approaches fosters collaboration among multidisciplinary teams, ensuring rigorous scientific standards and ethical practices in all research endeavors. Through her work, van Laarhoven contributes significantly to the understanding and treatment of complex diseases, ultimately aiming to bridge the gap between research findings and clinical application.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, Noord Holland, Netherlands
Patients applied
Trial Officials
H.W.M. van Laarhoven, Prof. Dr.
Principal Investigator
secretariaat.oncologie@amsterdamumc.nl
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported